Glaxosmithkline Pharmaceuticals Limited Stock Fundamentals
| GLAXO Stock | 2,342 70.15 2.91% |
GlaxoSmithKline Pharmaceuticals Limited fundamentals help investors to digest information that contributes to GlaxoSmithKline Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline Pharmaceuticals stock.
At this time, GlaxoSmithKline Pharmaceuticals' Reconciled Depreciation is very stable compared to the past year. GlaxoSmithKline | Select Account or Indicator |
GlaxoSmithKline Pharmaceuticals Limited Company Profit Margin Analysis
GlaxoSmithKline Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current GlaxoSmithKline Pharmaceuticals Profit Margin | 0.19 % |
Most of GlaxoSmithKline Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, GlaxoSmithKline Pharmaceuticals Limited has a Profit Margin of 0.1896%. This is 101.69% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all India stocks is 114.93% lower than that of the firm.
GlaxoSmithKline Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GlaxoSmithKline Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare GlaxoSmithKline Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlaxoSmithKline Pharmaceuticals competition to find correlations between indicators driving GlaxoSmithKline Pharmaceuticals's intrinsic value. More Info.GlaxoSmithKline Pharmaceuticals Limited is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.41 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for GlaxoSmithKline Pharmaceuticals Limited is roughly 2.46 . Comparative valuation analysis is a catch-all model that can be used if you cannot value GlaxoSmithKline Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GlaxoSmithKline Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.GlaxoSmithKline Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline Pharmaceuticals by comparing valuation metrics of similar companies.GlaxoSmithKline Pharmaceuticals is currently under evaluation in profit margin category among its peers.
GlaxoSmithKline Fundamentals
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 387.39 B | ||||
| Shares Outstanding | 169.41 M | ||||
| Shares Owned By Insiders | 75.58 % | ||||
| Shares Owned By Institutions | 8.46 % | ||||
| Price To Book | 24.43 X | ||||
| Price To Sales | 11.16 X | ||||
| Revenue | 34.54 B | ||||
| Gross Profit | 19 B | ||||
| EBITDA | 8.87 B | ||||
| Net Income | 5.9 B | ||||
| Total Debt | 186.65 M | ||||
| Book Value Per Share | 97.18 X | ||||
| Cash Flow From Operations | 5.82 B | ||||
| Earnings Per Share | 39.79 X | ||||
| Target Price | 2914.5 | ||||
| Number Of Employees | 3.21 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 397.25 B | ||||
| Total Asset | 35.74 B | ||||
| Retained Earnings | 8.76 B | ||||
| Working Capital | 12.73 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 35.74 B |
About GlaxoSmithKline Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 75.5 M | 71.7 M | |
| Total Revenue | 34.5 B | 27.6 B | |
| Cost Of Revenue | 21.7 B | 12.4 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline Pharmaceuticals financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline Pharmaceuticals security.